New drug treatments for urinary incontinence.
Urinary incontinence remains a common and distressing condition affecting many women and is known to have a significant effect on quality of life (QoL). Whilst conservative and behavioural therapy are important in the management of women with both stress incontinence and overactive bladder (OAB) ultimately many may benefit from pharmacological therapy. Antimuscarinic drugs are the commonly used agents in the treatment of OAB although often compliance and persistence are affected by adverse effects. Consequently many newer agents remain under investigation. In addition duloxetine has recently been introduced for the management of women with stress incontinence and may offer an alternative to surgery in selected cases. The aim of this review is to provide an overview of the current and new developments in the management of women with urinary incontinence as well as reviewing the role of oestrogen therapy in relation to lower urinary tract dysfunction.
Robinson
Dudley
D
Department of Urogynaecology, 3rd Floor, Golden Jubilee Wing, Kings College Hospital, London, UK. dudley.robinson@nhs.net
Cardozo
Linda
L
D000928:Antidepressive Agents / Q000627:therapeutic use; D050034:Antidiuretic Agents / Q000627:therapeutic use; D016587:Antimutagenic Agents / Q000627:therapeutic use*; D000068736:Duloxetine Hydrochloride; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D006801:Humans; D017410:Practice Guidelines as Topic; D013876:Thiophenes / Q000627:therapeutic use; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D014549:Urinary Incontinence / Q000188:drug therapy*
D000928:Antidepressive Agents; D050034:Antidiuretic Agents; D016587:Antimutagenic Agents; D004967:Estrogens; D013876:Thiophenes; D000068736:Duloxetine Hydrochloride